Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492936 | 0.81 | CES2 (0.45) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL2791051 | 0.79 | GSK3B (0.46) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL7607766 | 0.79 | CES2 (0.43) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL27691009 | 0.79 | CA2 (0.42) | ALDH1A1HTTCA2DAO | |
| SCHEMBL11725003 | 0.79 | CES2 (0.43) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL7384491 | 0.78 | DAO (0.44) | ALDH1A1MEN1HTTSMN1; SMN2CA2 | |
| SCHEMBL13067953 | 0.76 | CES2 (0.45) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL26349154 | 0.75 | ALDH1A1 (0.42) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL2332944 | 0.75 | HSP90AB1 (0.43) | LMNAALDH1A1CES2CES1GSK3B | |
| SCHEMBL13028665 | 0.75 | CES2 (0.39) | LMNAALDH1A1CES2CES1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1814871-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006053791-A2 | COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | LMNA 4234/4885ALDH1A1 437/4885CES2 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.